Is Thermo Fisher Scientific (TMO) a risky stock?
As of July 21, 2026, Clavix grades Thermo Fisher Scientific (TMO) B+ for risk, a composite score of 79 out of 100 on an A+ to F scale, which puts TMO in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind TMO's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how TMO scores on each, as of July 21, 2026.
What's moving TMO's risk right now
Company-specific signals Clavix flags behind TMO's current grade, drawn from recent news and filings as of July 21, 2026.
The outbreak underscores growing demand for rapid, multiplexed molecular diagnostic solutions for gastrointestinal pathogens, which is a relevant tailwind for Thermo Fisher's (TMO…
The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.
In-line guidance removes a near-term catalyst in either direction, leaving the rating dependent on longer-term execution.
What a B+ grade means
On the Clavix A+ to F scale, TMO's composite of 79 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell TMO or any security. Grades are risk indicators, not predictions of return. Data may be delayed.